| 作者：May Feng Chen , Nurazzahra binti Kamarudin ... |
| 来源：[J].Advances in Modern Oncology Research, 2017, Vol.3 (6)PiscoMed Publishing |
| 摘要：Background: Pazopanib was listed in MOH, Malaysia’s drug formulary on July 2013 for the treatment of mRCC. Two landmark trials were used to support the listing i.e. VEG105192 and COMPARZ which showed a median progression free survival (PFS) of 9.2 and 8.4 months respe... |
全文获取